Prolonged response of relapsed high grade serous ovarian carcinoma to the oral angiokinase inhibitor nintedanib in a patient with a germline BRCA1 mutation

Gynecologic Oncology Reports

Volumn 3, Issue , 2013, Pages 7-10

  Wong, Han Hsi ^a   Parkinson, Christine ^a   Ledermann, Jonathan A ^b   Brenton, James D ^c   Merger, Michael ^d   Shaw, Ashley ^a   Patterson, Aileen ^a   Shafi, Mahmood ^a   Earl, Helena M ^e  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c CANCER RESEARCH UK CAMBRIDGE RESEARCH INSTITUTE   (United Kingdom)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e Experimental Cancer Medicine Centre and NIHR Cambridge Biomedical Research Centre   (United Kingdom)

Author keywords

Angiogenesis; BIBF 1120; BRCA; Nintedanib; Ovarian cancer; VEGF

Indexed keywords

CA 125 ANTIGEN; CAPECITABINE; CARBOPLATIN; CISPLATIN; EPIRUBICIN; NINTEDANIB; PACLITAXEL; PLACEBO; PLATINUM COMPLEX;

ADULT; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CASE REPORT; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; GENE MUTATION; GERM LINE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPHADENOPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; TREATMENT DURATION; TUMOR SUPPRESSOR GENE;

EID: 84868620923     PISSN: None     EISSN: 2211338X     Source Type: Journal    
DOI: 10.1016/j.gynor.2012.10.003     Document Type: Article

References (10)

1. Ledermann J.A., Hackshaw A., Kaye S., Jayson G., Gabra H., McNeish I., et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J. Clin. Oncol. 2011, 29:3798-3804.
2. Tagawa T., Morgan R., Yen Y., Mortimer J. Ovarian cancer: opportunity for targeted therapy. J. Oncol. 2012, 2012:682480.
3. Burger R.A., Brady M.F., Bookman M.A., Fleming G.F., Monk B.J., Huang H., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 2011, 365:2473-2483.
4. Perren T.J., Swart A.M., Pfisterer J., Ledermann J.A., Pujade-Lauraine E., Kristensen G., et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 2011, 365:2484-2496.
5. Aghajanian C., Blank S.V., Goff B.A., Judson P.L., Teneriello M.G., Husain A., et al. OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 2012, 30:2039-2045.
6. Pujade-Lauraine E., Hilpert F., Weber B., Reuss A., Poveda A., Kristensen G., et al. AURELIA: a randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC) [abstract]. J. Clin. Oncol. 2012, 30:LBA5002.
7. Kawai H., Li H., Chun P., Avraham S., Avraham H.K. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 2002, 21:7730-7739.
8. Navaraj A., Finnberg N., Dicker D.T., Yang W., Matthew E.M., El-Deiry W.S. Reduced cell death, invasive and angiogenic features conferred by BRCA1-deficiency in mammary epithelial cells transformed with H-Ras. Cancer Biol. Ther. 2009, 8:2417-2444.
9. Tarnowski B., Chudecka-Glaz A., Gorski B., Rzepka-Górska I. Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients. Breast Cancer Res. Treat. 2004, 88:287-288.
10. Kang H.J., Kim H.J., Rih J.K., Mattson T.L., Kim K.W., Cho C.H., et al. BRCA1 plays a role in the hypoxic response by regulating HIF-1alpha stability and by modulating vascular endothelial growth factor expression. J. Biol. Chem. 2006, 281:13047-13056.